Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Watson Says Received Favorable Ruling Over Generic Sanctura XR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2012 | 12:19am CEST

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACTAVIS INC
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
08/24DJPfizer Buys Part of AstraZeneca's Antibiotics Business
08/09DJBotox Maker Allergan's Revenue Climbs, but Loss More Than Doubles -- WSJ
08/08DJAllergan Revenue Increases, Though Loss Widens--Update
08/08DJMARKET SNAPSHOT : Stocks Back Off All-time Highs As Health-care Stocks Slump
08/08DJMARKET SNAPSHOT : Stocks Retreat From Records As Health-care Stocks Slump
08/08DJU.S. Stocks Slip Despite Surge in Energy Sector
08/05DJPFIZER : Business Groups Sue Over Inversion Rules -- WSJ
08/04DJPFIZER : Business Groups Sue U.S. Government Over Tax-Inversion Rules -- 2nd Upd..
08/04 Business groups sue over new U.S. limit on tax-driven foreign buyouts
More news
Sector news : Pharmaceuticals - NEC
08:49aDJBusiness Watch -- WSJ
08/29 Mylan to launch generic EpiPen at half the price of original
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
08/29DJROCHE : Receives US FDA Emergency Use Authorization for Zika Test -- Update
08/29DJROCHE : Receives US FDA Emergency Use Authorization for Zika Test
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ($)
Sales 2016 14 806 M
EBIT 2016 7 609 M
Net income 2016 -
Debt 2016 -
Yield 2016 -
P/E ratio 2016 8,35
P/E ratio 2017 422,59
Capi. / Sales 2016 6,33x
Capi. / Sales 2017 5,79x
Capitalization 93 702 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 299 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Brenton L. Saunders President, Chief Executive Officer & Director
Paul M. Bisaro Executive Chairman
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC93 702
JOHNSON & JOHNSON16.74%328 086
PFIZER INC.8.77%212 965
ROCHE HOLDING LTD.-12.84%212 954
NOVARTIS AG-10.83%208 887
MERCK & CO., INC.19.29%174 236
More Results